ciprofloxacin hydrochloride

This page contains recent news articles, when available, and an overview of ciprofloxacin hydrochloride but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Overview:

ciprofloxacin hydrochloride
(when available)

Pharmacology and use:
Ciprofloxacin, a broad-spectrum antiinfective agent of the fluoroquinolone class, is used to treat gram-negative infections, sexually transmitted diseases, mycobacterial infections, corneal ulcers, and bacterial conjunctivitis. For the treatment of Bacterial infection of Respiratory tract, UTI, Uncomplicated Cystitis in females, GI, Chronic Bacterial Prostatitis, CNS, Immuno compromised patients, Skin, Bone and Joint Infections, Uncomplicated cervical and urethral gonorrhea

Mechanism Of Action:
Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive organisms. Ciprofloxacin inhibits bacterial DNA gyrase, an enzyme responsible for counteracting excessive supercoiling of DNA during replication or transcription. The mechanism of action of quinolones, including ciprofloxacin, is different from that of other antimicrobial agents such as beta-lactams, macrolides, tetracyclines, or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin. There is no known cross-resistance between ciprofloxacin and other classes of antimicrobials.

News Articles on Ciprofloxacin

www.PicksThatMove.com: "Picks that move" Alerts, August 10, 2009 ...  -  ‎Aug 10, 2009‎
Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections. TMCnet

Depomed to Present at Canaccord Adams' 29th Annual Global Growth ...  -  ‎Aug 11, 2009‎
Proquin ® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections. PharmaLive.com (press release)

Transconjunctival Orbital Invasion by Methicillin-Resistant ...  -  13 Jul 2009
5 Approximately 96% of MRSA ocular isolates are resistant to ciprofloxacin hydrochloride and 82% are resistant to levofloxacin. Archives of Ophthalmology

ARDM | ALXA | MNKD | ALKS  -  ‎Jun 22, 2009‎
The best near-term catalyst on the horizon is the initiation of a phase IIb program with the inhaled liposomal ciprofloxacin hydrochloride (ILCH) candidate PR-Inside.com (Pressemitteilung)

10-K/A: GENESIS PHARMACEUTICALS ENTERPRISES, INC.  -  ‎Apr 10, 2009‎
These increases are attributable to continued strong sales of our best selling products, Ciprofloxacin Hydrochloride tablets, Itopride Hydrochloride MarketWatch (press release)

Genesis Pharmaceuticals Affirms Operating Income Guidance, Adjusts ...  -  ‎Apr 2, 2009‎
However, the Company will not change its marketing method or sales structure with respect to the sale of its low margin Ciprofloxacin Hydrochloride tablets PR Newswire (press release)

Depomed Completes Enrollment of Serada’s Full Phase 3 Clinical ...  -  ‎Apr 2, 2009‎
Proquin ® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is Business Wire (press release)

Depomed Completes Enrollment of Serada's Full Phase 3 Clinical ...  -  ‎Apr 3, 2009‎
Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is PipelineReview.com (press release)

10-K: DEPOMED INC  -  ‎Mar 6, 2009‎
Inc. Proquin(R) XR (ciprofloxacin hydrochloride extended release tablets) is a once-daily treatment for uncomplicated urinary tract infections that we MarketWatch (press release)

Depomed Reports Fourth Quarter and Year-End 2008 Financial Results  -  ‎Mar 5, 2009‎
Proquin ® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is Business Wire (press release)

Depomed Completes Enrollment of Breeze 1 Phase 3 Clinical Trial ...  -  ‎Mar 2, 2009‎
Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is MarketWatch (press release)

StandoutStocks.com: "Stocks that Standout" picks for today are ...  -  ‎Feb 20, 2009‎
Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is Trading Markets (press release)

Depomed Completes Enrollment Of Breeze 1 Phase 3 Clinical Trial ...  -  ‎Mar 4, 2009‎
Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is Medical News Today (press release)

Depomed to Present at the Cowen and Company 29th Annual Healthcare ...  -  ‎Mar 10, 2009‎
Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is PR-Inside.com (Pressemitteilung)

Genesis Pharma Boosts Product Portfolio with Purchase of TCM ...  -  04 Feb 2009
Hydrochloride granules (a digestive aid), Ciprofloxacin Hydrochloride tablets (bacterial antibiotic), and Paracetamol tablets (analgesic for flu). Seeking Alpha,

Depomed to Present at Upcoming Conferences  -  Feb 3, 2009
Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is MarketWatch (press release)

Aradigm reports positive results from Phase II bronchiectasis trial  -  Jan 27, 2009
The patients were randomized into two equal size groups, one receiving 3ml of inhaled liposomal ciprofloxacin hydrochloride (ILCH) and the other receiving Pharmaceutical Business Review

Aradigm announces positive mid-stage results of ILCH in treatment ...  -  Jan 21, 2009
OB: News ) announced positive top-line results from a Phase 2 clinical trial of inhaled liposomal ciprofloxacin hydrochloride, or ILCH, in patients with RTT News,

Aradigm reports positive results from Phase II bronchiectasis trial  -  Jan 22, 2009
The patients were randomized into two equal size groups, one receiving 3ml of inhaled liposomal ciprofloxacin hydrochloride (ILCH) and the other receiving Pharmaceutical Business Review

Federal Trade Commission Files Complaint Against Par ...  -  Feb 2, 2009
2006), and by the Federal Circuit in In re Ciprofloxacin Hydrochloride Antitrust Litigation, 544 F.3d 1323 (Fed. Cir. 2008). No federal court has adopted PR Newswire (press release),

Depomed Announces Management Promotions  -  Jan 9, 2009
Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is PR-Inside.com (Pressemitteilung),

Federal Circuit Holds Reverse Payment Patent Settlements Lawful ...  -  Jan 22, 2009
...(+1 212 918 3100) or by email (ejstock@hhlaw.com). (1) In Re: Ciprofloxacin Hydrochloride Antitrust Litigation, Case No 2008-1097 (Fed Cir October 15 2008). International Law Office,

Herbal antidotes for food poisoning, snake venom  -  24 Dec 2008
The researchers compared the adsorptive potential of Garcinia kola seed (GKS) for ciprofloxacin hydrochloride (CIP) with that of a standard adsorbent and a The Guardian - Nigeria,

United States: Cash Payments To Settle Hatch-Waxman Litigation Do ...  -  Dec 1, 2008
Bayer owns a patent directed to compounds that exhibit antibacterial properties, specifically ciprofloxacin hydrochloride, the active ingredient in Cipro®. Mondaq News Alerts (registration),

Depomed, Inc. Announces Conference Call to Discuss Exclusive North ...  -  21 Nov 2008
Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is MarketWatch

Depomed, Inc. Announces Exclusive North American License Agreement ...  -  21 Nov 2008
Proquin ® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is PharmaLive.com (press release),

Depomed, Inc. Announces Conference Call to Discuss Exclusive North ...  -  21 Nov 2008
Proquin® XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is PR-Inside.com (Pressemitteilung),

Paying Off Your Generic Drug Competition? No Problem.  -  Oct 31, 2008
Specifically, it covers ciprofloxacin hydrochloride, the active ingredient in Cipro®. The patent expired on December 9, 2003 but the FDA granted Bayer an Patent Baristas,

Depomed Reports Third Quarter 2008 Financial Results  -  Oct 30, 2008
Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is Trading Markets (press release),

Depomed Initiates Second Phase 3 Trial in Menopausal Hot Flashes  -  21 Oct 2008
Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is MarketWatch

Some Newsmakers In Pharma Sector - Weekly Wrap  -  Oct 18, 2008
The active ingredient ciprofloxacin hydrochloride in Bayer's antibiotic Cipro was issued a patent in June 1987. The drug was approved by the FDA in October Trading Markets (press release),

Genesis Pharma Books 31% Higher Revenues in 2008  -  Oct 2, 2008
Ciprofloxacin Hydrochloride tablets – an antibiotic. Produced $2.5 million in revenue last year but now being phased out. For a short period of time, Seeking Alpha,

Depomed Announces Presentation of Clinical Data at the North ...  -  Sep 25, 2008
Proquin(R) XR (ciprofloxacin hydrochloride) is approved in the United States for the once-daily treatment of uncomplicated urinary tract infections and is Trading Markets (press release),

Depomed's ProQuin(R) XR Achieves First Marketing Authorization in ...  -  Jul 23, 2008
Depomed's ProQuin XR is exclusively licensed to Rottapharm/Madaus for Europe and is a once-daily extended-release formulation of ciprofloxacin hydrochloride FOXBusiness

Depomed Reports Second Quarter 2008 Financial Results  -  Jul 31, 2008
ProQuin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary StreetInsider.com (subscription),

Depomed to Announce Second Quarter 2008 Financial Results on July ...  -  Jul 17, 2008
ProQuin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary MarketWatch

Depomed Achieves Tier 2 Reimbursement Status for Glumetza(R) With ...  -  Jul 9, 2008
Proquin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary FOXBusiness

The Michael J. Fox Foundation Awards Depomed a Preclinical ...  -  Jul 23, 2008
Proquin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary FOXBusiness

Santarus and Depomed Announce US Promotion Agreement for GLUMETZA ...  -  Jul 22, 2008
ProQuin ® XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary Business Wire (press release),

Other News To Note  -  Jul 23, 2008
...a once-daily, extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. TMCnet

Depomed Secures $15 Million in Non-Dilutive Funding for Hot Flash ...  -  Jun 30, 2008
Proquin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary FOXBusiness

Depomed Announces Allowance of Additional US Patent Covering ...  -  Jun 17, 2008
Proquin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary Genetic Engineering News (press release),

Depomed to Present at the 7th Annual Needham & Co. Biotechnology ...  -  02 Jun 2008
ProQuin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary Centre Daily Times,

Q&A: About Anthrax  -  May 29, 2008
A. The preferred antibiotic, ciprofloxacin hydrochloride -- brand name Cipro -- is prescribed for 60 days. Doxycycline, also called tetracycline, Virginia Gazette,

Depomed Elects Karen A. Dawes to Board of Directors  -  Apr 8, 2008
ProQuin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary FOXBusiness

Depomed Reports Preliminary 2007 Year End Financial Results  -  Mar 6, 2008
ProQuin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary StreetInsider.com (subscription),

Depomed Reports Preliminary 2007 Year End Financial Results  -  Mar 6, 2008
...of the company’s license and supply agreements with Esprit Pharma for ProQuin ® XR (ciprofloxacin hydrochloride) in the third quarter of 2007. Business Wire (press release),

United States: FTC Takes 4-in-1 Shot At Reverse Payment ...  -  Feb 28, 2008
The proper legal standard for reverse payment settlements is currently before that circuit in In re Ciprofloxacin Hydrochloride Antitrust Litigation, No. Mondaq News Alerts (subscription),

Depomed to Present at the BIO CEO & Investor Conference  -  Feb 5, 2008
ProQuin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary FOXBusiness

Dutton Associates Announces  -  Jan 15, 2008
Laiyang Jiangbo?s core products include clarithromycin sustained-release tablets, itopride hydrochloride granules, ciprofloxacin hydrochloride tablets, Ad-Hoc-News (Pressemitteilung),

Depomed and King Pharmaceuticals Terminate Promotion Agreement for ...  -  Oct 29, 2007
Proquin® XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary WELT ONLINE,

Marksans Pharma gets European approval  -  Sep 26, 2007
Ciprofloxacin Hydrochloride is mainly used to treat bacterial infections. Shares of the firm closed at Rs 103.10, up 4.99 per cent at the BSE. Economic Times,

Depomed Announces Retirement of Chief Financial Officer John F ...  -  Oct 11, 2007
Proquin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary Trading Markets (press release),

Marksans Pharma up on European nod for drug  -  Sep 25, 2007
CHENNAI: Marksans Pharma shares gained on the BSE after the company said that it has received certificate of suitability for its ciprofloxacin hydrochloride Hindu Business Line,

Depomed, Watson Expand ProQuin XR Promotion Deal To Obstetrics ...  -  Sep 25, 2007
ProQuin XR is a once-daily, extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. RTT News,

SubSea Resources FY07 Loss Widens - Quick Facts [SUB.L]  -  Sep 25, 2007
The companies specified that the ProQuin XR is a once-daily, extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated RTT News,

Depomed to Present at Thomas Weisel Partners Annual Healthcare ...  -  Aug 29, 2007
Proquin ® XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary Business Wire (press release),

Depomed Announces Positive Results of Phase 2a Proof-of-Concept ...  -  Sep 5, 2007
Proquin(R) XR (ciprofloxacin hydrochloride) extended release tablets are approved in the United States for the once-daily treatment of uncomplicated urinary Genetic Engineering News (press release),

[an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive] Brand Names/Synonyms:
ciprofloxacin hydrochloride is also known by the following brand names and/or synonymsBacquinor; Baycip; Bernoflox; CIPROFLOXACIN HCL; Ciflox; Cifloxin; Ciloxan; Ciprinol; Cipro; Cipro I.V.; Cipro Xl; Cipro Xr; Ciprobay; Ciprocinol; Ciprodar; Ciprofloxacin; Ciprofloxacin Base; Ciprofloxacin Dihydrochloride; Ciprofloxacin Hydrochloride; Ciprofloxacin Monohydrochloride; Ciprofloxacina; Cipromycin; Ciproquinol; Ciproxan; Ciproxin; Flociprin; Floxin; Floxin Otic; Floxin in Dextrose 5%; Ocuflox; Ofloxacin; Proquin Xr; Septicide; Velomonit

Drug Category:
ciprofloxacin hydrochloride is categorized under the following by the FDA: Anti-Infectives; Quinolones; ATC:J01MA02; ATC:S01AX13; ATC:S03AA07

Dosage Forms:
LIQUID; OINTMENT; SOLUTION; SUSPENSION; TABLET; TABLET (COMBINED RELEASE); TABLET (EXTENDED-RELEASE)

Absorption:
70-80%

Interactions:
-->Interactions for Ciprofloxacin:

Caffeine

Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its serum half-life.

Cyclosporine

Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.

Glyburide

The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.

Histamine H2-receptor antagonists

Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of ciprofloxacin.

Methotrexate

Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate. This might increase the risk of methotrexate toxic reactions. Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.

Multivalent Cation-Containing Products

Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired. Proquin XR should be administered at least 4 hours before or 2 hours after these products. This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.

Non-steroidal anti-inflammatory drugs (but not aspirin)

These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.

Omeprazole

The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion. Omeprazole should be taken as directed and Proquin XR should be taken with a main meal of the day, preferably the evening meal..

Phenytoin

Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.

Probenecid

Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.

Theophylline

As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life. This may result in increased risk of theophylline-related adverse reactions. If concomitant use cannot be avoided, serum levels of theophylline should be monitored and dosage adjustments made as appropriate.

Warfarin

Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be monitored.





Chemical IUPAC Name:
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1H-quinoline-3-carboxylicacid

:
 
Web health.mongabay.com/health


Health Home | Conditions | Cancer | Medications | Surgery | Vaccines

mongabay.com


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.

IF YOU NEED A LINK/TEXT REMOVED FROM THIS PAGE, PLEASE CONTACT: mongabay (at) gmail.com


COPYRIGHT 2007 MONGABAY.COM